<DOC>
	<DOC>NCT01124643</DOC>
	<brief_summary>This study will evaluate safety and clinical outcomes of treatment with Replagal in adult participants with Fabry disease who have completed Study TKT028 (NCT00864851).</brief_summary>
	<brief_title>Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of ReplagalÂ® in Adult Patients With Fabry Disease</brief_title>
	<detailed_description>HGT-REP-060 was designed to provide participants who participated in TKT028 an additional 52 weeks of treatment with Replagal at the standard dose of 0.2 milligram per kilogram (mg/kg) every other week (EOW) to assess the effect of continued Replagal therapy on long-term safety and clinical outcomes for this participant population.</detailed_description>
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Complete all study requirements and assessments for Study TKT028 less than 30 days (+/ 7 days) prior to the first dose in this extension protocol Voluntarily signed an Institutional Review Board/Independent Ethics Committee approved informed consent form after all relevant aspects of the study have been explained and discussed. Has received and tolerated at least 80% of the total planned Replagal infusions in Study TKT028 Female participants of childbearing potential must agree to use a medically acceptable method of contraception at all times during the study and must have a negative pregnancy test at the time of study entry and as required throughout participation in study Has received treatment with any investigational drug (other than Replagal) or device within 30 days prior to study entry. Is unable to comply with the protocol, (eg, is unable to return for safety evaluations, or is otherwise unlikely to complete the study), as determined by the Investigator Has a positive test for hepatitis B surface antigen (HBsAg), hepatitis C(HCV) antibody, or human immunodeficiency virus (HIV) antibody Is pregnant or lactating Is morbidly obese, defined as body mass index (BMI) &gt;39 kg/m2 Has any safety or medical issues, as assessed by the Investigator, that contraindicate participation in the study (eg, has experienced an adverse reaction to treatment with Replagal or has a known hypersensitivity to any of the components of Replagal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Replagal</keyword>
	<keyword>Agalsidase alfa</keyword>
	<keyword>Alpha-Galactosidase</keyword>
	<keyword>Enzyme Replacement Therapy</keyword>
</DOC>